Leptospirosis is a disease caused by bacteria Leptospira. It can infect multiple species of mammals, including humans, dogs, rats, mice, raccoons, skunks, opossums, cows and pigs. Once infected, mammals may present with a variety of clinical manifestations. While the classical presentation of the disease is easily recognised by experienced clinicians practising in endemic regions, atypical systemic manifestations can be missed. In this case report, we describe the atypical manifestations of orchitis and balanoposthitis in a five-year-old male intact dog from Los Angeles County, California with confirmed leptospirosis. The dog was infected with serovar Canicola, which is uncommon for this region. Awareness of these atypical manifestations would hopefully guide clinicians towards early diagnosis.

Difficulties related to storage and transport of currently available live oral rotavirus vaccines can have detrimental consequences on the efficacy of the vaccines. Thus, there is a great need for thermostable vaccines that can eliminate the necessity for cold chain storage or reconstitution before administration. In this study, we developed a dissolvable oral polymeric film comprised of a live attenuated thermostable tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) powder and antacid (CaCO3). Immunogenicity and protective efficacy of the vaccine after buccal delivery was evaluated in the gnotobiotic pig model of human rotavirus (HRV) infection and diarrhea. Two doses of the vaccine were highly immunogenic and conferred strong protection against virus shedding and diarrhea upon challenge with a high dose of a virulent G1 HRV in gnotobiotic pigs. Those pigs vaccinated with the preserved film vaccine had significantly delayed onset of diarrhea; reduced duration and area under the curve of diarrhea; delayed onset of fecal virus shedding; and reduced duration and peak of fecal virus shedding titers compared to pigs in both the placebo and the reconstituted liquid oral RRV-TV vaccine groups. Associated with the strong protection, high titers of serum virus neutralization antibodies against each of the four RRV-TV mono-reassortants and G1 HRV-specific serum IgA and IgG antibodies, as well as intestinal IgA antibodies, were induced by the preserved film vaccine. These results demonstrated the effectiveness of our thermostable buccal film rotavirus vaccine and warrant further investigation into the promise of the novel technology in addressing drawbacks of the current live oral HRV vaccines.